Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided adjuvant osimertinib after surgery in early-stage EGFR-mutant non-small cell lung cancer
ChiCTR2200062836Phase 4Not yet recruiting
- Sponsor
- The Fourth People's Hospital of Kunming
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Fourth People's Hospital of Kunming. Primary endpoint: Disease-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062836.